P. Terence's most recent trade in Adma Biologics Inc was a trade of 136,363 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on July 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | P. Terence Kohler | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 136,363 | 136,363 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | P. Terence Kohler | CFO and Treasurer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jul 2026 | 85,130 | 143,149 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Ind Inc | Terence P. Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 395 | 2,822 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Ind Inc | Terence P. Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2026 | 544 | 2,427 (0%) | 0% | 0 | Common Stock | |
| Limbach Holdings Inc | Terence Patrick Dugan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jan 2026 | 1,498 | 1,498 | - | - | Restricted Stock Units | |
| Flexsteel Ind Inc | Terence P. Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2025 | 589 | 1,883 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Ind Inc | Terence P. Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Sep 2025 | 504 | 1,294 (0%) | 0% | 0 | Common Stock | |
| Flexsteel Ind Inc | Terence P. Calloway | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 790 | 790 (0%) | 0% | 0 | Common Stock | |
| OptiNose Inc | P. Terence Kohler | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 45,000 | 0 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | P. Terence Kohler | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 30,541 | 0 (0%) | 0% | - | Common Stock | |
| OptiNose Inc | P. Terence Kohler | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 21 May 2025 | 6,950 | 0 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | P. Terence Kohler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 13,875 | 23,875 (0%) | 0% | 0 | Common Stock | |
| OptiNose Inc | P. Terence Kohler | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2025 | 6,950 | 6,950 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | P. Kohler Terence | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2024 | 675,000 | 675,000 | - | - | Stock Option (Right to Buy) | |
| OptiNose Inc | P. Kohler Terence | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Oct 2024 | 150,000 | 150,000 (0%) | 0% | 0 | Common Stock | |
| Verrica Pharma Inc | P. Terence Kohler | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 2.66 per share. | 26 Aug 2024 | 21,820 | 52,596 (0%) | 0% | 2.7 | 58,041 | Common Stock |
| Verrica Pharma Inc | P. Terence Kohler | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 2.46 per share. | 26 Aug 2024 | 7,899 | 44,697 (0%) | 0% | 2.5 | 19,432 | Common Stock |
| Verrica Pharma Inc | P. Terence | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.93 per share. | 14 Nov 2023 | 18,452 | 44,048 (0%) | 0% | 2.9 | 54,064 | Common Stock |
| Verrica Pharma Inc | P. Terence | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.97 per share. | 14 Nov 2023 | 9,632 | 34,416 (0%) | 0% | 3.0 | 28,607 | Common Stock |
| Verrica Pharma Inc | P. Terence Kohler | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Aug 2023 | 125,000 | 125,000 (0%) | 0% | 0 | Common Stock | |
| Verrica Pharma Inc | P. Terence | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 85,000 | 85,000 | - | - | Employee Stock Option (right to buy) |